Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%

Healthcare

Page 63
  1. Feb 10, 2026 · 16:13 · MBX

    Microbix adds CAP as QAP customer

    Microbix adds CAP as QAP customer

    01
  2. Feb 10, 2026 · 16:04 · NRX

    NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

    NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

    02
  3. Feb 10, 2026 · 11:28 · VIVI

    Tempramed launches products in Israel's Super-Pharm

    Tempramed launches products in Israel's Super-Pharm

    03
  4. Feb 10, 2026 · 09:00 · GSD

    DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY

    DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY

    04
  5. Feb 10, 2026 · 07:30 · HELP

    Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

    Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

    05
  6. Feb 10, 2026 · 07:28 · CRDL

    Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

    Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

    06
  7. Feb 10, 2026 · 07:01 · THRM

    Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

    Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

    07
  8. Feb 10, 2026 · 07:01 · TLT

    Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

    Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

    08
  9. Feb 10, 2026 · 03:01 · VIVI

    TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy

    TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy

    09
  10. Feb 09, 2026 · 17:54 · RX

    BioSyent to acquire Oral Science for $25.5-million

    BioSyent to acquire Oral Science for $25.5-million

    10
  11. Feb 09, 2026 · 17:00 · MSCL

    Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares

    Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares

    11
  12. Feb 09, 2026 · 07:30 · RX

    BioSyent to Acquire Oral Science Inc.

    BioSyent to Acquire Oral Science Inc.

    12
  13. Feb 09, 2026 · 07:28 · ARCH

    Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

    Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

    13
  14. Feb 09, 2026 · 07:03 · VITA

    Vitalist and MicroEJ Partner with BENIO to Launch First VitalOS(TM) Powered Smartwatch in Asia

    Vitalist and MicroEJ Partner with BENIO to Launch First VitalOS(TM) Powered Smartwatch in Asia

    14
← Newer Older →